Skip to main content

The Efficacy of Adipokines and Indices of Metabolic Syndrome as Predictors of Severe Obesity-Related Hepatic Steatosis

Digestive Diseases and Sciences volume 51, Article number: 1716 (2006) Cite this article

Abstract

The aim of this study was to investigate adiponectin, leptin, and metabolic syndrome as predictors of the severity of obesity-related steatosis. By ultrasonography steatosis-positive (cases) subjects (n=141) were compared with controls (n=111). Demographic and anthropometric data and serum concentrations of adiponectin, leptin, and insulin were measured. The impact of several criteria of metabolic syndrome, serum adiponectin concentrations, and serum leptin concentrations were tested using a multivariate logistic regression analysis. The frequency of metabolic syndrome was higher in cases (44.0% versus 9.2%; P < .0001). Cases were older and had higher insulin resistance, waist circumference, and lower concentrations of adiponectin (all P < .001). The upper adiponectin quartile was associated with a lesser grade of steatosis. Metabolic syndrome and adiponectin concentrations were independently associated with the probability of steatosis. In conclusion, adipokines and metabolic syndrome are useful indices for the prediction of the severity of obesity-related steatosis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84–89

    PubMed  Article  CAS  Google Scholar 

  2. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295

    PubMed  Article  CAS  Google Scholar 

  3. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461–2468

    PubMed  Article  CAS  Google Scholar 

  4. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953

    PubMed  Article  CAS  Google Scholar 

  5. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K, Saruta T (2002) Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103:137–142

    CAS  Article  Google Scholar 

  6. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM (2002) Plasma adiponectin levels in overweight and obese Asians. Obes Res 10:1104–1110

    PubMed  CAS  Google Scholar 

  7. Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA (2002) Plasma adiponectin concentrations in children: Relationships with obesity and insulinemia. J Clin Endocrinol Metab 87:4652–4656

    PubMed  Article  CAS  Google Scholar 

  8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935

    PubMed  Article  CAS  Google Scholar 

  9. Mendez-Sanchez N, Chavez-Tapia NC, Villa AR, Sanchez-Lara K, Zamora-Valdes D, Ramos MH, Uribe M (2005) Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 11:1737–1741

    PubMed  CAS  Google Scholar 

  10. MacDougald OA, Hwang CS, Fan H, Lane MD (1995) Regulated expression of the obese gene product (leptin) in white adipose tissue and 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 92:9034–9037

    PubMed  Article  CAS  Google Scholar 

  11. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM (1995) Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543–546

    PubMed  Article  CAS  Google Scholar 

  12. Mendez-Sanchez N, Gonzalez V, King-Martinez AC, Sanchez H, Uribe M (2002) Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr 132:2195–2198

    PubMed  CAS  Google Scholar 

  13. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang PL, Sinha MK, Considine RV (1996) Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 348:159–161

    PubMed  Article  CAS  Google Scholar 

  14. Wolf G, Hamann A, Han DC, Helmchen U, Thaiss F, Ziyadeh FN, Stahl RA (1999) Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis [see comments]. Kidney Int 56:860–872

    PubMed  Article  CAS  Google Scholar 

  15. Frank S, Stallmeyer B, Kampfer H, Kolb N, Pfeilschifter J (2000) Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 106:501–509

    PubMed  CAS  Google Scholar 

  16. Ring BD, Scully S, Davis CR, Baker MB, Cullen MJ, Pelleymounter MA, Danilenko DM (2000) Systemically and topically administered leptin both accelerate wound healing in diabetic ob/ob mice. Endocrinology 141:446–449

    PubMed  Article  CAS  Google Scholar 

  17. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N (2001) Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 34:288–297

    PubMed  Article  CAS  Google Scholar 

  18. Angulo P (2002) Treatment of nonalcoholic fatty liver disease. Ann Hepatol 1:12–19

    PubMed  Google Scholar 

  19. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, Hamasaki K, Kato Y, Eguchi K, Yukawa K, Ishii N (2002) Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 97:1796–1801

    PubMed  Article  CAS  Google Scholar 

  20. Scheen AJ, Luyckx FH (2002) Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 16:703–716

    PubMed  Article  CAS  Google Scholar 

  21. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745–750

    PubMed  Article  Google Scholar 

  22. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502

    PubMed  CAS  Google Scholar 

  23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419

    PubMed  Article  CAS  Google Scholar 

  24. Kissebah AH, Krakower GR (1994) Regional adiposity and morbidity. Physiol Rev 74:761–811

    PubMed  CAS  Google Scholar 

  25. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770

    PubMed  Article  CAS  Google Scholar 

  26. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409–2415

    PubMed  CAS  Article  Google Scholar 

  27. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y (1996) Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nat Med 2:800–803

    PubMed  Article  CAS  Google Scholar 

  28. Bacha F, Saad R, Gungor N, Arslanian SA (2004) Adiponectin in youth: Relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 27:547–552

    PubMed  CAS  Google Scholar 

  29. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599

    PubMed  CAS  Google Scholar 

  30. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–1133

    PubMed  CAS  Google Scholar 

  31. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58

    PubMed  Article  CAS  Google Scholar 

  32. Mendez-Sanchez N, Chavez-Tapia NC, Uribe M (2004) [An update on non-alcoholic fatty liver disease]. Rev Invest Clin 56:72–82

    PubMed  Google Scholar 

  33. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292–295

    PubMed  Article  CAS  Google Scholar 

  34. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570–578

    PubMed  Article  CAS  Google Scholar 

  35. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345–1350

    PubMed  Article  CAS  Google Scholar 

  36. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME (1998) The biology of leptin: A review. J Anim Sci 76:1405–1420

    PubMed  CAS  Google Scholar 

  37. Guo KY, Halo P, Leibel RL, Zhang Y (2004) Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr Comp Physiol 287:R112–119

    PubMed  CAS  Google Scholar 

  38. Marra F (2002) Leptin and liver fibrosis: A matter of fat. Gastroenterology 122:1529–1532

    PubMed  Article  Google Scholar 

  39. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM (1997) Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 94:2557–2562

    PubMed  Article  CAS  Google Scholar 

  40. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD (2004) Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 41:943–949

    PubMed  Article  CAS  Google Scholar 

  41. Lang T, Ikejima K, Yoshikawa M, Enomoto N, Iijima K, Kitamura T, Takei Y, Sato N (2004) Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor. Biochem Biophys Res Commun 323:1091–1095

    PubMed  Article  CAS  Google Scholar 

  42. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 287:356–359

    PubMed  Article  Google Scholar 

  43. Ford ES, Giles WH (2003) A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26:575–581

    PubMed  Google Scholar 

  44. Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Valles V, Rios-Torres JM, Franco A, Olaiz G, Rull JA, Sepulveda J (2003) Analysis of the agreement between the World Health Organization criteria and the National Cholesterol Education Program-III definition of the metabolic syndrome: Results from a population-based survey. Diabetes Care 26:1635

    PubMed  Google Scholar 

  45. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917–923

    PubMed  Article  Google Scholar 

  46. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH (2004) Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40:1387–1395

    PubMed  Article  Google Scholar 

  47. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR (2004). Nonalcoholic steatohepatitis: Histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 35:1070–1082

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico

    Nahum Méndez-Sánchez, Norberto C. Chávez-Tapia, Karla Sánchez-Lara, Guadalupe Ponciano-Rodríguez, Martha H. Ramos & Misael Uribe

  2. Seccion de Estudios de Posgrado e Investigacion Escuela Superior de Medicina-IPN, Mexico, DF, Mexico

    Roberto Medina-Santillán

  3. Clinical Epidemiology Unit, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico

    Antonio R. Villa

Authors
  1. Nahum Méndez-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norberto C. Chávez-Tapia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roberto Medina-Santillán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio R. Villa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Karla Sánchez-Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guadalupe Ponciano-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Martha H. Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Misael Uribe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nahum Méndez-Sánchez.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Méndez-Sánchez, N., Chávez-Tapia, N.C., Medina-Santillán, R. et al. The Efficacy of Adipokines and Indices of Metabolic Syndrome as Predictors of Severe Obesity-Related Hepatic Steatosis. Dig Dis Sci 51, 1716 (2006). https://doi.org/10.1007/s10620-006-9093-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10620-006-9093-5

Keywords:

  • Adiponectin
  • Hepatic steatosis
  • Liver
  • Fatty liver
  • Leptin
  • Metabolic syndrome